Bioqual (OTCMKTS:BIOQ – Get Rating) and bioAffinity Technologies (NASDAQ:BIAF – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Bioqual and bioAffinity Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bioqual | 0 | 0 | 0 | 0 | N/A |
| bioAffinity Technologies | 0 | 0 | 0 | 0 | N/A |
Institutional & Insider Ownership
2.4% of bioAffinity Technologies shares are held by institutional investors. 39.2% of Bioqual shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Bioqual and bioAffinity Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bioqual | 5.28% | 8.85% | 5.33% |
| bioAffinity Technologies | N/A | N/A | N/A |
Earnings & Valuation
This table compares Bioqual and bioAffinity Technologies’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bioqual | $66.15 million | N/A | $5.26 million | $3.84 | 19.79 |
| bioAffinity Technologies | N/A | N/A | -$8.15 million | N/A | N/A |
Bioqual has higher revenue and earnings than bioAffinity Technologies.
Summary
Bioqual beats bioAffinity Technologies on 6 of the 7 factors compared between the two stocks.
About Bioqual
Bioqual, Inc. engages in the provision and development of medical research and consulting services to commercial clients and government laboratories. It focuses on animal models of human diseases including COVID-19, Zika, AIDS, Influenza, RSV, Malaria, and other infectious disease areas. The company was founded by John C. Landon on June 1, 1981 and is headquartered in Rockville, MD.
About bioAffinity Technologies
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Receive News & Ratings for Bioqual Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bioqual and related companies with MarketBeat.com’s FREE daily email newsletter.